Business Operations:

Sector: Healthcare
Industry: Healthcare Plans

Humana Inc. provides medical and specialty insurance products in the United States. It operates in two segments, Insurance and CenterWell. The Insurance segment offers individual Medicare Advantage products, including health insurance benefits, including wellness programs, chronic care management, and care coordination; individual Medicare stand-alone prescription drug products (PDP); group Medicare advantage and Medicare stand-alone PDP; Medicare supplements; specialty and ancillary insurance comprising dental, vision, life and disability; and administrative services to arrange health care services for active-duty and retired military personnel and dependents, as well as pharmacy benefit managers. Its CenterWell segment operates full-service, value-based senior focused primary care centers under the Conviva Senior Primary Care and CenterWell Senior Primary Care brands; a management services organization; CenterWell Home Health, a home health provider; and OneHome, which manages post-acute patient needs, as well as provides pharmacy and hospice solutions. The company was formerly known as Extendicare Inc. and changed its name to Humana Inc. in April 1974. Humana Inc. was founded in 1961 and is headquartered in Louisville, Kentucky.

Revenue projections:

Revenues for Humana Inc. are expected to drop compared to the previous year, which could be a cause for concern for investors. A decline in earnings may negatively impact the company's profitability, leading cautious investors to reconsider their positions, as it often signals challenges in overall financial health.

Financial Ratios:

currentRatio	1.74200
forwardPE	23.40598
debtToEquity	76.48500
earningsGrowth	0.27100
revenueGrowth	0.26200
grossMargins	0.13653
operatingMargins	0.03465
trailingEps	10.52000
forwardEps	16.59234

HUM's current ratio of 1.742 means the company has enough liquidity to meet its short-term debt obligations. With sufficient cash reserves and current assets, HUM can comfortably cover its liabilities, reflecting a strong financial outlook.
HUM's Forward PE being in a good range suggests that its stock price is aligned well with earnings. The stock is not considered overpriced, offering room for future growth, which makes it an appealing investment opportunity with the potential for value appreciation.
HUM's positive earnings and revenue growth reflect an optimistic outlook for the company's future. The growth in these key areas indicates that HUM is expected to continue expanding its business and boosting its financial performance in the coming periods.
HUM's forward EPS being higher than its trailing EPS points to expected growth in profitability. This suggests that the company is projected to perform better in the current financial year, with higher earnings forecasted compared to the previous year.

Price projections:

HUM's price projections have been revised upward over time, suggesting that analysts are becoming more confident in the company's future. This trend points to increased optimism about HUM's ability to grow.

Insider Transactions:

There were 1 transactions to buy HUM stock, with market price of 181.16000366210938.During the period under review, no buy transactions were recorded.HUM has experienced more selling activity at current price levels, which could suggest a bearish outlook. If the trend of increased selling continues, it may result in further price declines for the stock.

Recommendation changes over time:

With analysts showing a buy bias for HUM, investors may be more inclined to see the stock as an attractive investment. The favorable outlook could spur increased interest, positioning HUM as a safe and profitable place for investors to allocate their funds and seek growth.